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Abstract
BACKGROUND—Quality improvement in primary care has focused on improving adult 
immunization.
OBJECTIVES—Test the effectiveness of a step-by step, evidence-based guide, the 4 Pillars™ 
Immunization Toolkit, to increase adult pneumococcal vaccination.
DESIGN—Randomized controlled cluster trial (RCCT) in Year 1 (6/1/2013–5/31/2014) and a 
pre-post study in Year 2 (6/1/2014–1/31/2015) with data analyzed in 2016. Baseline year was 
6/1/2012–5/31/2013. Demographic and vaccination data were derived from de-identified EMR 
extractions.
SETTING—25 primary care practices stratified by city (Houston, Pittsburgh), location (rural, 
urban, suburban) and type (family medicine, internal medicine), randomized to receive the 
intervention in Year 1 (n=13) or Year 2 (n=12).
PARTICIPANTS—A cohort of 18,107 patients ≥65 years at baseline with a mean age of 74.2 
years; 60.7% were women, 16.5% were non-white and 15.7% were Hispanic.
INTERVENTION—The Toolkit, provider education, and one-on-one coaching of practice-based 
immunization champions. Outcome measures were 23-valent pneumococcal polysaccharide 
vaccine (PPSV) and pneumococcal conjugate vaccine (PCV) rates and percentage point (PP) 
changes.
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RESULTS—In the RCCT, all intervention and control groups had significantly higher PPSV 
vaccination rates with average increases ranging from 6.5–8.7 PP (P<0.01). The intervention was 
not related to higher likelihood of PPSV vaccination. In the Year 2 pre-post study, the likelihood of 
PPSV and PCV vaccination was significantly higher in the active intervention sites than the 
maintenance sites in Pittsburgh, but not in Houston.
CONCLUSION—In a randomized controlled cluster trial, both intervention and control groups 
increased PPSV among adults ≥65 years. In a pre-post study, private primary care practices using 
the 4 Pillars™ Immunization Toolkit significantly improved PPSV and PCV uptake compared 
with practices that were in the maintenance phase of the study.
Keywords
Immunization; adults; pneumococcal polysaccharide vaccine; pneumococcal conjugate vaccine; 
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INTRODUCTION
Adult immunizations have been garnering increased attention as an important area for 
quality improvement for several reasons. Firstly, Healthy People 2020 goals for vaccines 
given to adults have not been met. In 2013, United States’ (U.S.) pneumococcal vaccination 
uptake was 21.2% among those 19–64 years with high risk conditions,1 compared with a 
goal of 60%,2 and 59.7% among those ≥65 years,1 compared with a goal of 90%.2 Secondly, 
the National Quality Strategy (NQS) established under the Affordable Care Act has set a 
long term goal to “promote healthy living and well-being through receipt of effective clinical 
preventive services across the lifespan in clinic and community settings.”3 The Center for 
Medicare and Medicaid Services has also made reporting of influenza and pneumococcal 
vaccines one requirement for providers to avoid negative payment adjustments.4 Clearly, 
adult immunizations are viewed as an integral part of quality care.
Provider barriers to adult vaccination include economic barriers arising from Medicare 
coverage that varies among vaccines, inconvenient vaccine storage in some medical offices, 
urgent and chronic medical conditions competing with time for prevention efforts, 
uncertainty about the patient’s vaccination status, missed immunization opportunities, and 
lack of patient and provider reminders.5–10 Patient-related barriers include not knowing that 
a vaccine was recommended, not believing that the clinician recommended the vaccine, and 
fear of vaccine side effects.11–14 Facilitators of vaccination include standing order programs 
(SOPs), prompts from the electronic medical record, use of teamwork, and longer time with 
the physician.15
Based on a comprehensive literature review, The Community Preventive Services Task Force 
found that improving vaccination uptake requires behavior changes at the system, provider, 
support staff, and patient levels.16 Sustainable change requires a coordinated, multipronged, 
adaptable approach; hence, the need for a practice improvement toolkit that can support 
change among diverse practice cultures is evident. The 4 Pillars™ Immunization Toolkit 
(Toolkit) is the product of years of health services research on the barriers to and facilitators 
of adult immunizations from the provider and patient perspectives,17,18 national and local 
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surveys,5,6,19 and pilot studies on a toolkit to increase use of standing orders for adult 
vaccines.20
We undertook a 2-year study of 25 primary care practices to test the effectiveness of the 
Toolkit for increasing uptake of pneumococcal polysaccharide vaccine (PPSV) and in year 2, 
the newly recommended 13-valent pneumococcal conjugate vaccine (PCV) among adults 
ages 65 and older. The purpose of this study was to report the effect of the intervention on 
pneumococcal vaccination rates, percentage point differences and likelihood of 
pneumococcal vaccination. The data are presented in two ways. The randomized controlled 
cluster trial (RCCT) analysis compared changes in vaccine uptake in the intervention and 
control groups at the end of Year 1. In Year 2, controls were crossed over into active 
intervention and the Year 1 intervention groups became maintenance groups. Year 2 data 
were analyzed using a pre-post design in which changes in vaccine uptake were measured 
from the end of Year 1 to the end of the Year 2 intervention.
METHODS
The baseline year was 6/1/2012–5/31/2013. The RCCT took place during Year 1 (6/1/2013–
5/31-2014) and the pre-post study took place during Year 2 (6/1/2014–1/31/2015). The new 
CDC recommendations for PCV were published and payment discussions with the Centers 
for Medicare and Medicaid Services occurred in the fall of 2014. This trial was approved by 
the Institutional Review Boards of the University of Pittsburgh, Baylor College of Medicine 
and the Harris Health System.
Sample Size and Sites
Optimal Design software (University of Michigan, Version 1.77. 2006) was used to calculate 
sample size for a RCCT seeking a 10–15% absolute increase in vaccination rate, and a 
minimum practice size of 100 patients. A sample size of 20 clusters or sites (10 Intervention 
and 10 Control practices) was determined to be necessary to achieve 80% power with an 
alpha of 0.05. Eligible primary care family medicine (FM) and internal medicine (IM) 
practices from a practice-based research network (PBRN) in Pittsburgh (FM Pittnet), a 
clinical network in Southwestern Pennsylvania (Community Medicine, Inc.) and a PBRN of 
safety net practices in Houston (SPUR-Net) were solicited for participation. When 25 sites 
agreed to participate, solicitation ceased. All sites used a common electronic medical record 
(EMR), EpicCare within their respective health systems.
Cluster Randomization
Cluster randomization allocates clinical practices rather than individuals to the intervention 
arms.21 Some practices had more than one site; thus each site was considered as a cluster. 
Eligibility requirements included having at least 100 patients ≥18 years of age, preliminary 
baseline vaccination rates for at least one adult vaccine (influenza, pneumococcal, Tdap) 
<50% and a willingness to make office changes to increase vaccination rates. Participating 
practices were stratified first by city (Pittsburgh or Houston), location (urban, suburban or 
rural), and discipline (internal or family medicine). The practices were then randomized into 
the Year 1 intervention or Year 2 intervention within strata (Figure 1). Year 2 intervention 
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sites (controls) were informed that their intervention would take place during Year 2 of the 
study and were not contacted again until the next year.
Toolkit
The 4 Pillars™ Immunization Toolkit is founded on four evidence-based16,22 key strategies: 
Pillar 1 - Convenient vaccination services; Pillar 2 – Communication with patients about the 
importance of immunization and the availability of vaccines; Pillar 3 - Enhanced office 
systems to facilitate immunization; Pillar 4 - Motivation through an office immunization 
champion (IC). Supplemental Table 1 describes some of the strategies contained in the 
Toolkit. The Toolkit includes background on the importance of protecting patients against 
vaccine-preventable diseases, barriers to increasing vaccination from both provider and 
patient perspectives and strategies to eliminate those barriers. Practices were expected to 
implement strategies from each of the 4 pillars.
In Year 1, the Toolkit was a printed and bound document, supplemented by a web-based 
practice transformation dashboard. The dashboard was developed from the work of Fixsen et 
al.23 who established an empirically-based implementation framework that includes 
systematic uptake, establishment, and maintenance of research findings into routine practice. 
The core components include: staff selection and training on the specific evidence-based 
practices, expert consultation and coaching of staff and administration, program evaluation 
to assess and provide feedback, facilitative administrative supports to ensure data are used to 
focus and inform decision making, and systems interventions.
Once the practice was registered, any staff member could log into the dashboard. The IC was 
responsible for registering the practice and its staff members, and identifying strategies that 
the practice would implement. The Toolkit provided step-by-step guidance for implementing 
the strategies, and the dashboard showed the practices’ progress through the change process. 
Practices could monitor their progress on graphs that reported biweekly numbers of vaccines 
given. In Year 2, the Toolkit was fully digitized to a website (4pillarstoolkit.pitt.edu) that 
incorporated all of the paper-based background information, as well as the dashboard 
capabilities.
Interventions
The intervention was designed using Diffusion of Innovations theory,24 and included the 
Toolkit, provider education, and one-on-one coaching of the immunization champion for 
each practice. One of two investigators (AEB, MPN) visited each intervention site to 
introduce the study and the Toolkit, and to work with staff to develop practice-specific ideas 
for implementing Toolkit strategies. Each practice identified an IC who was responsible for 
updating the practice transformation dashboard (Year 1) as intervention strategies were 
employed, and in Year 2 use the web-based Toolkit to guide strategy implementation and 
record progress in the dashboard, assisted by the research liaison as needed. Other tasks for 
the IC included participating in the biweekly telephone-call with a research liaison for 
coaching, ensuring that chosen strategies were being implemented and working to maintain 
motivation of the staff.
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The Toolkit was updated with new pneumococcal vaccination recommendations during Year 
2 at the end of September 2014, within a few days of their publication and each practice’s 
leadership team was directly notified by email of the changes to the pneumococcal 
recommendations. In November 2014, additional information was sent to the Pittsburgh 
practices about local insurance coverage for PCV vaccines. Information on CMS coverage 
for PCV was sent to all practices in early January 2015.
Data collection
De-identified demographic (date of birth, sex, race or ethnicity, health insurance coverage), 
office visit (dates) and vaccination data (vaccines given and dates) were derived from EMR 
data extractions performed by the UPMC Center for Assistance in Research using the 
eRecord and from a similar data extraction from the EMR by staff of the SPUR-NET for the 
Texas sites. Data extractions took place at the end of each year of the study. A longitudinal 
data base was created with only those patients who were ≥65 years at baseline and who had 
a visit each year during the three-year study period, creating a cohort of individuals who 
would have been patients of the practice during their practice’s respective baseline 
(6/1/2012–5/31-2013), control or intervention (Year 1; 6/30/2013–5/31/2014), and 
intervention or maintenance years (Year 2; 6/1/2014–1/31/2015).
Statistical analyses
Descriptive analyses were performed for patient demographic characteristics (age, sex, race, 
and ethnicity). Health insurance was not included in the regression analyses because all 
insurances would have covered pneumococcal vaccine in those aged ≥65 years. Because of 
significant differences in patient populations, size and structure of the practices in Houston 
and Pittsburgh, these sites were grouped separately for analysis. Age was used as a 
continuous variable. Race and ethnicity were recorded differently in each city. In Pittsburgh, 
with few Hispanic patients, ethnicity was rarely recorded; hence patients were grouped by 
race into white and non-white with blacks and Hispanics assigned to the non-white group 
and only race data are presented and used in analysis. In Houston, with few non-Hispanic 
patients, race was rarely recorded; hence only ethnicity (Hispanic and non-Hispanic) are 
presented and used in analysis.
The two pneumococcal vaccines (PPSV and PCV) would typically be administered once 
during the 3-year project period (PCV was a new recommendation late in Year 2). The 
analytical periods were baseline: 6/1/2012–5/31/2013; Year 1: 6/1/2013–5/31/2014; and 
Year 2: 6/1/2014–1/31/2015. Proportions were reported for categorical variables and means 
and standard deviations were reported for continuous variables. The primary outcome 
measures were the cumulative PPSV and PCV vaccination rates reported at baseline, Year 1 
and Year 2. Chi-square tests were performed to test for differences in cumulative vaccination 
rates at different time points.
Year 1 RCCT analyses
To determine which factors were related to PPSV vaccination while accounting for the 
clustered nature of the data, Cox proportional hazard models with the robust sandwich 
estimate were fitted, taking account of heterogeneity in demographic characteristics 
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(including age, sex, and race/ethnicity). Because of the lack of variability in the number of 
strategies used by practices and the correlation of strategies with intervention group, only 
intervention group was included in the models.
Year 2 Pre-post analyses
At the end of Year 1, practices were offered the opportunity to continue active intervention 
during Year 2. Four practices opted to do so. At the same time, the Year 1 control sites began 
the intervention. For the pre-post analyses, the four practices in Pittsburgh that continued the 
intervention in Year 2 were combined with the Year 1 control sites and were referred to as 
the active intervention group. The six practices that did not actively participate in Year 2 
were referred to as the maintenance group. In Houston, the Year 1 intervention sites were 
referred to as the maintenance group and the Year 1 control sites that received the 
intervention in Year 2 were referred to as the active intervention group. Cox proportional 
hazard models with the robust sandwich estimate were again fitted, taking account of 
heterogeneity in demographic characteristics (including age, sex, and race/ethnicity) to 
determine which factors were related to PPSV and PCV uptake. Statistical significance of 
two-sided tests was set at a type I error (alpha) equal to 0.05. All analytical procedures were 
performed using SAS® 9.3.
RESULTS
Twenty-four sites completed the intervention; the demographic and other characteristics for 
patients ≥65 years are shown in Table 1. The large differences between practices in Houston 
and Pittsburgh supported the separate analyses of sites by city. Houston sites were larger 
practices with higher reported proportions of Hispanic patients, higher proportions of female 
patients, and non-commercially insured patients than the Pittsburgh sites.
Year 1 RCCT study
Cumulative PPSV vaccination rates for all patients ≥65 years at each site and by intervention 
group at Baseline and Year 1 are shown in Table 2. Individual practice baseline rates for 
PPSV ranged from a high of 80.9% to a low of 31.0% with average baseline rates of 71.4% 
and 67.7% for the intervention groups in Pittsburgh and Houston, respectively.
At the end of the intervention year, PPSV rates increased significantly in both intervention 
and control groups in both cities. Increases ranged from 6.5 to 8.7 PP (P<0.001 by Chi 
square test for baseline to Year 1 rates). The differences in PP changes between intervention 
and control groups were significant for Houston sites (P<0.001), but not for Pittsburgh sites 
(P=0.84).
Regression analyses that accounted for the clustered nature of the data as well as race/
ethnicity, age, and sex, were conducted to determine the effect of the intervention on 
vaccination rates in the RCCT (Table 3). The likelihood of PPSV vaccination in Year 1 was 
not related to the intervention but was significantly related to younger age (P<0.001) in the 
Pittsburgh sites. Similarly, in Houston sites, younger age and non-Hispanic ethnicity, but not 
the intervention, were related to a higher likelihood of PPSV vaccination.
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Year 2 Pre-Post Study
At the end of the pre-post study comparing the Year 2 active intervention sites and the 
maintenance sites, individual site PPSV rates ranged from a low of 43.4% to a high of 94.7% 
(data not shown). Percentage point differences from Year 1 to Year 2 in the maintenance and 
active intervention sites are shown in Table 4. Active intervention and maintenance groups in 
both cities significantly improved PPSV vaccination rates from Year 1 to Year 2 (P<0.001). 
By the end of Year 2, 79% of practices (19/24) had PPSV rates at or above 70% and 58% of 
practices (14/24) had PPSV rates at or above 80% (data not shown).
PP differences in PCV vaccination rates for individual practices at the end of Year 2 are also 
shown in Table 4. Overall, the increase in PCV rates among active intervention sites was 
significantly greater than among the maintenance sites (P<0.001 for Pittsburgh sites and 
P<0.01 for Houston sites). Figure 2 shows PPSV and PCV vaccination rates for the active 
intervention and maintenance groups from baseline to the end of follow-up.
The likelihood of receipt of PPSV at the end of the pre-post study in Pittsburgh was 
significantly higher for the active intervention group, for males and for younger patients than 
for the maintenance group, females and older patients (P<0.05; Table 5). In the Houston 
sites there was no effect of the intervention on likelihood of PPSV receipt, but males and 
non-Hispanic patients were more likely to receive PPSV than female and Hispanic patients 
(P<0.001).
The effect of the intervention on the recently introduced PCV was marked; those in the 
active intervention group were 14.7 times more likely to receive PCV than the maintenance 
group. Age was related to likelihood of PCV vaccination but in this case it was the older 
patients who were more likely to receive the vaccine. In the Houston sites, there was no 
effect of the intervention on the likelihood of PCV receipt, although non-Hispanic patients 
were twice as likely to receive PCV as Hispanic patients (P=0.02) and older patients were 
slightly more likely to receive PCV (P<0.001).
DISCUSSION
National coverage for PPSV among adults ≥65 years of age was 59.7% in 2013, a level 
similar to recent years.1,25 In this study at baseline, many but not all, sites reported rates 
above that level, likely reflecting a segment of the population with access to primary care. 
Over the course of the RCCT, PPSV uptake increased significantly in both intervention and 
control groups and increased measurably in the majority of individual practices. During Year 
2, the active intervention group increased average PPSV rates by 4.6 to 5.2 percentage points 
while the maintenance groups continued to increase their average PPSV rates (2.4–6.5 
percentage points). These increases are considerably higher than recent secular trends. In 
previous research, we have reported that pediatric practices seem to reach a plateau in 
influenza vaccination rates at about 58%.26 This study shows that even practices with 
relatively high baseline vaccination rates can increase the proportion of their patients who 
receive PPSV, with a directed effort. Such increases will help practices achieve quality 
improvement goals as have been set forth by organizations such as the Centers for Medicare 
and Medicaid Services4 and the National Quality Strategy.3
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In both the RCCT and pre-post study, younger age was associated with higher likelihood of 
PPSV vaccination suggesting that practices targeted patients for PPSV vaccination as soon 
as they became 65 years old and this may be a successful strategy. There is no obvious 
explanation for why women were less likely to be vaccinated in the pre-post study, nor why 
non-Hispanic patients were more likely to receive PPSV in the RCCT but not in the pre-post 
study. However, these findings suggest that special efforts to market adult vaccines to 
population subgroups may be required in this setting.
Adoption and implementation, which are components of the RE-AIM evaluation 
framework,27,24 varied by setting according to reports from the research assistants, likely 
reflecting a variety of factors. Anecdotally, usability of the dashboard was a reported 
problem in Year 1, which was improved for Year 2. One practice served a religious sect that 
is hesitant about vaccination, another practice which serves a large immigrant community 
closed one of its two offices during Year 2, and another site was late in adoption of the 
intervention in Year 2.
In December 2011, FDA licensed PCV for use among adults ages 50 and older28 and the 
following June, ACIP recommended its use for adults ≥19 years of age with certain high risk 
and immunocompromising conditions.29 In September 2014, CDC recommended PCV for 
all adults ≥65 years of age to be given in series with PPSV.30 Hence, PCV was available and 
recommended for use among high risk patients, but was not age-based for adults at the time 
that the study began in 2013, and there are currently no national comparison data for PCV 
uptake. We report significantly higher likelihood of PCV vaccination in the active 
intervention groups compared with the maintenance groups, indicating a significant effect of 
the intervention on vaccination rates.
In late 2014, there was some confusion reported by the participating practices as to whether 
health insurance plans would cover administration of both vaccines and this may have 
delayed their uptake. This experience speaks to the need for easy-to-use resources such as 
the 4 Pillars™ Immunization Toolkit to help physicians and clinical staffs understand the 
implications of changing vaccine recommendations and reimbursement policies. Practices 
have been shown to improve implementation of interventions when they are well supported 
through a facilitator such as an IC,31,32 and specifically, to increase pneumococcal 
vaccination using clinician education and financial incentives.33
Strengths and Limitations
The strengths of this study are its randomized design, the large number and diversity of 
patients, diverse practice settings including safety net clinics, randomized design, and two 
intervention years of vaccination reporting. Limitations are that during the Year 1 
intervention, delivery of the EMR data was delayed, preventing the research team from 
providing feedback to the sites in both cities about their progress. The CDC’s change in 
recommendations regarding PCV late in Year 2 with the related confusion about Medicare 
coverage interfered with implementation. Given the increase in immunization rates in the 
control arm in Year 1, either intervention transference among study arms occurred in sites 
within the same network, a Hawthorne effect, or secular trends occurred; nationally, PPSV 
rates have been relatively flat, arguing against national secular trends.1
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In a randomized controlled cluster trial, both intervention and control groups increased 
PPSV among adults ≥65 years. In a pre-post study, small to medium sized private primary 
care practices using the 4 Pillars™ Immunization Toolkit significantly improved PPSV and 
PCV uptake compared with similar practices that were in the maintenance phase of the 
study. In large, safety net practices the intervention did not result in significant 
improvements in either PPSV or PCV uptake. The Toolkit may need enhancements to 
address the needs of this type of practice.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 2. a and b. Cumulative Pneumococcal Polysaccharide Vaccine (PPSV) Vaccination and 
Pneumococcal Conjugate Vaccine (PCV) Rates for Adults ≥65 Years at the End of Baseline and 
Year 2 by Intervention Group and City
*P<0.001 for percentage point (PP) difference from Baseline to Year 2 between Active 
Intervention and Maintenance groups by Chi-square test
Zimmerman et al. Page 14


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Zimmerman et al. Page 19
Table 3
Cox proportional hazard models to detect intervention effect on time to vaccination with pneumococcal 
polysaccharide vaccine for patients ages ≥ 65 years, adjusting for covariates
Year 1 - Randomized Controlled Cluster Trial Analysis 6/1/2013 – 5/31/2014
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Pittsburgh sites Houston sites
Intervention, ref. = Control 1.03 (0.78–1.37) 0.830 1.33 (0.94–1.88) 0.110
Female, ref. = Male 0.99 (0.87–1.13) 0.900 1.05 (0.90–1.21) 0.560
Age, years 0.92 (0.90–0.95) <0.001 0.95 (0.93–0.97) <0.001
White race, ref. = Non-white 0.88 (0.61–1.26) 0.520 – –
Non-Hispanic ethnicity, ref. = Hispanic – – 1.23 (1.03–1.48) 0.030
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